Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Chemotherapy Induced Anemia Clinical Trial

Official title:
A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Status Completed

Clinical Trial Summary

The purpose of this study is to find out if roxadustat (also known as FG-4592) is safe and effective for the treatment of anemia in participants receiving chemotherapy treatment for cancer.

Clinical Trial Description

This study consists of three periods: 1. Screening Period up to 28 days 2. Treatment Period of up to16 weeks 3. A Follow-up period of 4 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04076943
Study type	Interventional
Source	FibroGen
Contact
Status	Completed
Phase	Phase 2
Start date	August 20, 2019
Completion date	April 23, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05301517` - A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies	Phase 3
Terminated	`NCT00931606` - Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)	Phase 2
Completed	`NCT00272662` - Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144495` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3
Not yet recruiting	`NCT06075030` - A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy	Phase 2
Completed	`NCT00144482` - A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy	Phase 3